Original article by Jared Lynch
The Australian – Page: 17 & 27 : 13-Feb-20
CSL has posted a 2019-20 interim net profit of $US1.248bn, which is eight per cent higher than previously. Sales rose by 8.4 per cent to $US4.7bn, with sales of its immunoglobulin products rising by 26 per cent to $US1.985bn. The biotechnology group expects its full-year profit to be within the range of $US2.1bn to $US2.17bn. CEO Paul Perreault says none of the company’s employees in Wuhan have been infected by the coronavirus and the company has not yet been impacted by the outbreak.
CSL LIMITED – ASX CSL
Original article by Damon Kitney
The Australian – Page: 21 : 11-Sep-19
Shares in Melbourne-based stem cell developer Mesoblast rose by over 22 per cent on 10 September after it announced details of a strategic partnership with German drug company Grunenthal. The partnership will see the two companies work to develop and commercialise a cell therapy to threat severe lower back pain, with Mesoblast receiving up to $US150 million ($218.56 million) in upfront and milestone payments prior to the launch of any product developed under the partnership. Billionaire Alex Waislitz, who is one of Mesoblast’s investors, suggests the global potential for a non-opiate product for treating lower back pain could be worth "many billions of dollars" each year.
MESOBLAST LIMITED – ASX MSB, GRUNENTHAL GMBH
Original article by Sarah-Jane Tasker
The Australian – Page: 19 : 29-Aug-17
CSL has announced that it will spend $US91 million ($A114 million) on the purchase of US-based biotechnology company Calimmune. CSL executive Andrew Nash says the purchase of Calimmune gives it access to skills and technologies in the area of gene and cell-based therapies that it does not currently have. He said that CSL has had its eye on Calimmune, which has operations in both the US and Australia, for about a year.
CSL LIMITED – ASX CSL, CALIMMUNE INCORPORATED
Original article by Ben Potter
The Australian Financial Review – Page: 17 & 22 : 18-Aug-16
CSL has posted a 2015-16 net profit of $US1.24bn ($A1.6bn), which is 10 per cent lower than previously. The blood products and vaccines group’s sales rose by eight per cent to $US6.13bn. Earnings per share fell by eight per cent to $US2.69, but increased by seven per cent on a constant currency basis. CSL has forecast underlying net profit and EBITDA growth of 11 per cent and 14 per cent respectively in 2016-17. Its shares closed five per cent lower at $A110.84 on 17 August 2016.
CSL LIMITED – ASX CSL, SHIRE PHARMACEUTICALS GROUP PLC, NOVARTIS AG, CSL BEHRING, WILSONS ADVISORY AND STOCKBROKING LIMITED, SEQIRUS PTY LTD
Original article by Jessica Gardner, James Thomson
The Australian Financial Review – Page: 13 & 18 : 15-Jun-16
The market capitalisation of Australian biotechnology group Mesoblast has fallen to $A750m following a 42.2 per cent fall in its share price on 14 June 2016. The stock closed at a seven-year low of $A1.11 after Teva Pharmaceutical Industries advised that it will not finance the final round of clinical trials for Mesoblast’s stem-cell treatment for heart failure. Mesoblast had cash reserves of around $US100m at the end of the March quarter, and CEO Silviu Itescu is confident that the group can secure funding partners before its cash reserves are exhausted.
MESOBLAST LIMITED – ASX MSB, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, CEPHALON INCORPORATED, CANACCORD GENUITY (AUSTRALIA) LIMITED
Original article by Tim Binsted
The Australian Financial Review – Page: 15 : 12-Feb-16
Australian-listed Cochlear has posted a 2015-16 interim net profit of $A94m, which is 32 per cent higher than previously. Revenue also increased by 32 per cent, to $A581.7m, and sales of its hearing implants rose by 26 per cent to 14,748 units. CEO Chris Smith says the group has benefited from its consumer-focused strategy, and notes that the 65-plus age group represents a huge growth opportunity for Cochlear.
COCHLEAR LIMITED – ASX COH
Original article by Jessica Sier
The Australian Financial Review – Page: 18 : 8-Jan-16
Australia’s benchmark S&P/ASX 200 Index shed 2.7 per cent during 2015. However, an index of 40 biotechnology companies which was compiled by "Biotech Daily" gained 22 per cent. ImpediMed, Opthea, Nanosonics, Starpharma and Mesoblast are among the biotechnology stocks that could potentially perform well in 2016.
STANDARD AND POOR’S ASX 200 INDEX, BIOTECH DAILY, IMPEDIMED LIMITED – ASX IPD, OPTHEA LIMITED – ASX OPT, NANOSONICS LIMITED – ASX NAN, STARPHARMA HOLDINGS LIMITED – ASX SPL, MESOBLAST LIMITED – ASX MSB, HATCHTECH PTY LTD, SPINIFEX PHARMACEUTICALS PTY LTD, FIBROTECH THERAPEUTICS PTY LTD, QRXPHARMA LIMITED – ASX QRX, OSPREY MEDICAL INCORPORATED – ASX OSP, GI DYNAMICS INCORPORATED – ASX GID, CANACCORD GENUITY (AUSTRALIA) LIMITED, COCHLEAR LIMITED – ASX COH, CSL LIMITED – ASX CSL, RESMED INCORPORATED – ASX RMD
Original article by Tim Binsted
The Australian Financial Review – Page: 19 : 17-Nov-15
Mesoblast expects to raise $US63.8 million ($A95.8 million) by issuing American Depositary Shares (ADSs) in the US. The Australian-listed stem cell therapy group is offering ADSs at $US8 a unit, which implies that Mesoblast has a valuation of $A2.20 a share on the Australian stock exchange. Mesoblast shares declined 38.4 per cent to $A2.10 on 16 November 2015.
MESOBLAST LIMITED – ASX MSB, NASDAQ, STARPHARMA HOLDINGS LIMITED – ASX SPL
Original article by Jennifer Hewett
The Australian Financial Review – Page: 2 : 4-Aug-15
CSL is one of Australia’s most successful companies. It is a global player in the field of biotechnology. CFO Gordon Naylor complains about high tax rates in Australia which, he believes, hinder the development of the country’s advanced manufacturing sector. CSL advocates the introduction of a new tax rate of 10 per cent for advanced manufacturing. Under the current tax regime, Australian companies pay 30 per cent in corporate tax.
CSL LIMITED – ASX CSL, BLOOMBERG LP, AUSTRALIA. DEPT OF INDUSTRY AND SCIENCE
Original article by Joanna Mather
The Australian Financial Review – Page: 6 : 16-Jun-15
CSL’s CFO Gordon Naylor says the blood products group does not intend to reduce its manufacturing presence in Australia. However, he has conceded that CSL would have seriously considered building a $A500m plant in Australia if the nation’s 30 per cent corporate tax rate had been more competitive. CSL opted to build the facility in Switzerland, which has a company tax rate of 18 per cent. CSL has suggested that Australia adopt a tax rate of 10 per cent for advanced manufacturers.
CSL LIMITED – ASX CSL, CORPORATE TAX ASSOCIATION, MINERALS COUNCIL OF AUSTRALIA, ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT